Canada markets closed

Applied Therapeutics, Inc. (APLT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.8900+0.0250 (+2.89%)
At close: 04:00PM EDT
0.9100 +0.02 (+2.25%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.8650
Open0.8850
Bid0.8900 x 2200
Ask0.9000 x 800
Day's Range0.8600 - 0.9199
52 Week Range0.7280 - 22.2700
Volume428,953
Avg. Volume428,551
Market Cap23.351M
Beta (5Y Monthly)1.55
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Applied Therapeutics, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants

    NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the pricing of its underwritten public offering of 20.0 million shares of its common stock, par value $0.0001 per share, 10.0 million pre-funded warrants to purchase common stock in lieu of common stock to certai

  • GlobeNewswire

    Applied Therapeutics, Inc. Announces Public Offering of Common Stock and Warrants

    NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it plans to make a public offering of shares of its common stock, par value $0.0001 per share, or pre-funded warrants to purchase common stock in lieu of common stock to certain investors, and accompanying w

  • GlobeNewswire

    Applied Therapeutics Receives Orphan Medicinal Product Designation from the EMA for AT-007 for Treatment of Galactosemia

    NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced designation of AT-007 (gavorestat) as an orphan medicinal product by the European Medicines Agency (EMA) for treatment of Galactosemia (Galactosaemia). “We are pleased that the EMA has recognized the high unmet medical need in G